Biohaven Pharmaceutical (NYSE:BHVN) Shares Gap Down to $133.38

Shares of Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) gapped down prior to trading on Monday . The stock had previously closed at $133.38, but opened at $120.00. Biohaven Pharmaceutical shares last traded at $131.94, with a volume of 6,581 shares trading hands.

BHVN has been the topic of several analyst reports. Cantor Fitzgerald upped their price objective on Biohaven Pharmaceutical from $151.00 to $165.00 and gave the company an “overweight” rating in a research report on Monday, September 13th. Mizuho upped their price objective on Biohaven Pharmaceutical from $92.00 to $134.00 and gave the company a “buy” rating in a research report on Monday, July 12th. HC Wainwright upped their price objective on Biohaven Pharmaceutical from $111.00 to $135.00 and gave the company a “buy” rating in a research report on Thursday, July 8th. Zacks Investment Research raised Biohaven Pharmaceutical from a “strong sell” rating to a “hold” rating and set a $123.00 price objective on the stock in a research report on Monday, July 12th. Finally, Cowen upped their price objective on Biohaven Pharmaceutical from $90.00 to $130.00 and gave the company an “outperform” rating in a research report on Wednesday, July 7th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $124.27.

The firm has a fifty day moving average price of $126.85 and a two-hundred day moving average price of $98.85. The stock has a market capitalization of $8.73 billion, a P/E ratio of -9.31 and a beta of 1.03.

Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings data on Sunday, August 8th. The company reported ($3.23) EPS for the quarter, missing the consensus estimate of ($2.77) by ($0.46). The firm had revenue of $92.93 million during the quarter, compared to analysts’ expectations of $85.85 million. Biohaven Pharmaceutical’s quarterly revenue was up 858.3% compared to the same quarter last year. During the same period last year, the business earned ($2.55) EPS. As a group, research analysts anticipate that Biohaven Pharmaceutical Holding Company Ltd. will post -12.17 EPS for the current year.

Several large investors have recently bought and sold shares of the company. Thrivent Financial for Lutherans increased its stake in Biohaven Pharmaceutical by 185.1% in the 2nd quarter. Thrivent Financial for Lutherans now owns 1,416,890 shares of the company’s stock worth $137,552,000 after buying an additional 919,951 shares in the last quarter. BlackRock Inc. increased its stake in Biohaven Pharmaceutical by 24.0% in the 2nd quarter. BlackRock Inc. now owns 4,691,578 shares of the company’s stock worth $455,460,000 after buying an additional 908,024 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in Biohaven Pharmaceutical in the 1st quarter worth $49,082,000. Glenview Capital Management LLC purchased a new stake in Biohaven Pharmaceutical in the 1st quarter worth $31,345,000. Finally, Armistice Capital LLC increased its stake in Biohaven Pharmaceutical by 74.8% in the 1st quarter. Armistice Capital LLC now owns 1,000,000 shares of the company’s stock worth $68,350,000 after buying an additional 428,000 shares in the last quarter. Hedge funds and other institutional investors own 92.14% of the company’s stock.

About Biohaven Pharmaceutical (NYSE:BHVN)

Biohaven Pharmaceutical Holding Co Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators.

Read More: What is the QQQ ETF?

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.